Drug Development - clinical trials phase I: 25-45 healthy volunteers [safety evaluation] phase II: 20-150 diseased individuals [safety and efficacy] phase.

Slides:

Advertisements

Similar presentations

ANTIBODY ENGINEERING Joud Shafiq.

Advertisements

The Drug Discovery Process

Drug design and testing,. Drug Names Chemical name- describes its molecular structure and distinguishes it from other drugs.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.

Monoclonal antibody Phage displayed antibody

Monoclonal Antibodies NIS Uralsk. Medical use of Antibodies Monoclonal antibodies (mAbs) are pure, single antibody types that are industrially produced.

Monoclonal antibodies Anticancer therapy Weihua Wu.

Immunity 6.5 Antibodies.

By Claire Baldock © Boult Wade Tennant 2011 Therapeutic Antibodies – Technical Introduction AIPPI Forum Hyderabad Pharma Workshop.

Monoclonal antibodies Hybridoma Technique. Monoclonal antibodies (mAb or moAb) Monoclonal antibodies are:  monospecific antibodies that are identical.

Stages of drug development

MONOCLONAL ANTIBODIES

Patent issue. Currently known to causes apoptotic cell death, cellular proliferation, differentiation, inflammation, and viral replication promoting.

September 30, 2005 Lan-Yang Ch’ang, Ph.D. Institute of Biomedical Sciences Academia Sinica Scientific Impacts to the Biotech.

Live (virulent) virus Disease Immune response What happens when you get infected? DeathSurvive (Immune) OR.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

ABDUALLAH SAUD AL-SHETELY

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Biotechnology and Medicine Esmaeil Sadroddiny, PhD Medical Biotechnology.

Monoclonal Antibodies Aims: Must be able to define the term monoclonal antibody. Should be able to outline the possible uses of monoclonal antibodies.

Recombinant DNA in Medicine Industry- Monoclonal Antibodies Topics in Nanobiotechnology- April Maria Viviana Duarte.

Monoclonal Antibodies. IMMUNOTHERAPY Treatment of the disease by Inducing, Enhancing or Suppressing the Immune System. Active Immunotherapy: - It stimulates.

Monoclonal Antibodies Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

Immunity [Innate and Acquired Immunity]. Biotechnology RED: Medical Area GREEN: Agriculture/Food Science WHITE: Bioprocess Engineering.

Antibody ( immunoglobulin) Serum protein electrophoresis (SEP) Serum protein electrophoresis (SEP) Basic structure and function of immunoglobulin. Basic.

Developing medicines for the future and why it is challenging Angela Milne.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

Monoclonal Antibodies. THE IMMUNE SYSTEM DEFINITION: - The integrated body system of organs, tissues, cells & cell products that differentiates self from.

Cancer Immunotherapy. Type of tumor: -Non-invasive (benign) - Invasive (malignant)

항체의약품 개발의 최근 동향 Hyo Jeong Hong Laboratory of Immunology KRIBB.

LOGO Dr. Nermin Hassan KSU Microbiology section.

1 now require 7.6 years on average to complete the clinical development process and receive marketing approval, Total development and approval times for.

httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.

FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.

Inventions Research & Development (R&D) in Pharmaceuticals DISCOVERY Enzymes, receptors, & genetics, DEVELOPMENT Safety, quality and efficacy tests PRODUCTION.

Drug Development Process Stages involved in Regulating Drugs

giovedi 20 Aprile Lezione generale sui principi della microscopia

Drug Discovery &Development

Appendix III: Scope of Service of CUHK Service Units

Globular Protein Made of amino acid chains

Biotechnology Objectives: At the end of this lecture we will be able to identify and describe the uses of biotechnology in society.

chimeric antigen receptor T-cell therapy for ALL

The Lifecycle of Pharmaceutical products

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Vh domain Single domain antibodies represent the smallest antibody that was proven of diagnostic and therapeutic usefulness. They are antibody fragments.

Single domain antibody library Single domain antibodies represent the smallest antibody that was proven of diagnostic and therapeutic usefulness. They.

Single chain antibody library Why single domain antibodies are preferred? Single domain antibodies represent the smallest antibody that was proven of diagnostic.

Sdab library antibodies from camelized human antibodies. In particular, single domain antibodies combine the benefits of conventional antibodies with important.

Antibody domain Single domain antibodies represent the smallest antibody that was proven of diagnostic and therapeutic usefulness. They are antibody fragments.

Phagemid display Phage display is one of the most powerful and widely used laboratory technique for the study of protein-protein, protein-peptide and protein-DNA.

Phage display company Creative Biolabs is one of the well-recognized experts who is professional in applying advanced phage display technologies for a.

Recombinant antibody Creative Biolabs is a pioneer of recombinant antibody (rAb) discovery and manufacture, providing the most comprehensive list of rAb.

Tandem bites Creative Biolabs possesses unchallenged experience in antibody development and recombinant protein synthesis. Multiple platforms of Creative.

Phage display system Creative Biolabs is one of the well-recognized experts who is professional in applying advanced phage display technologies for a broad.

Phage display method Antibody libraries are constructed by the genomic information coding for antibody variable domains, which can be derived from B cells.

Bacteriophage display Antibody libraries are constructed by the genomic information coding for antibody variable domains, which can be derived from B cells.

Therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a.

Gpcr antibody With rich experience in antibody discovery and membrane protein studies, experts from Creative Biolabs have launched a cutting-edge membrane.

Recombinant antibody Creative Biolabs is a pioneer of recombinant antibody (rAb) discovery and manufacture, providing the most comprehensive list of rAb.

Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.

Dog antibody As a recognized leader in the field of phage display and antibody engineering, Creative Biolabs is specialized in producing monoclonal rabbit,

Human antibody discovery Based on the technology of B cell sorting, Creative Biolabs provides Native™ human antibody discovery service to generate native.

Phage panning Creative Biolabs is one of the well-recognized experts who is professional in applying advanced phage display technologies for a broad range.

New genes can be added to an organism’s DNA.

Drug design and testing,

Innovation & the Pharmaceutical Research & Development Industry

Drug Design and Drug Discovery

Presentation transcript:

Drug Development - clinical trials phase I: healthy volunteers [safety evaluation] phase II: diseased individuals [safety and efficacy] phase III: hundreds to thousands patients multi-center, double-blind, placebo-controlled randomized clinical trial (RCT) protocol phase IV: vigilant post-marketing surveillance - toxicity : major cause of drug rejection

Biotech. Industry

Biotech. & Pharm.

Biological drugs in Pharm.

Drug approvals

Antibody drugs 항체약품 저분자 화합물 약품 전임상 이전 개발 기간 1-2 년 5 년 개발 비용 2 백만불 20 백만불 부작용 예측 쉽다. 어렵다. 개발 실패 드물다. 가끔 있다. 전체적 특성 독성드물다. 예측하기 힘들다. 라이선스판매 임상 I 이후 임상 II 이후 성공율 20% 5% 이하 한 공장에서 여러 약품 생산 긴 반감기. 생산비 $ /g 매우 낮다.

Biological drugs

Antibody industry

More than 400 antibodies are in clinical trial currently. The annual sale of biological drugs in 2003 was $30 billion. The annual sale of therapeutic antibodies in 2003 was $7.2 billion. (Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook, AS Insights, June 1, 2004)AS Insights More than 100 antibodies will be approved before (V. Bryan Lawlis, Diosynth ATP in Cary, NC) The market size of antibodies will be $26 billion in (Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook, AS Insights, June 1, 2004)AS Insights

Approved Therapeutic Abs AntibodyTarget IndicationSalesProducer (million $) OKT3CD3Acute kidney transplantation rejection (Ortho Biotech/J & J) DigibindDigoxinDigoxin poisoning (Glaxo/Welcome) Herceptin HER- 2 Metastatic.breast cancer (03) (Genentech/MedImmune) 117.7(2Q/04) ZenapaxIL2 R-aKindney transplantation rejection (Protein Design Labs/Roche) SimulectIL2 R-aAcute organ rejection (Norvatis) RituxanCD20Non-Hodgkin’s lymphoma1,489.1 (03) (Genentech/Roche) * 424.7(2Q/04) PanorexCA17-1AColorectal cancer (GlaxoSmithKline / Centocor) RemicadeTNFaCrohn’s disease & Rheumatoid arthritis (02)(Centocor/Schering-Plough) * ReoproPlateletIschemic cardiac complications (02)(Centocor/Eli Lilly) * SynagisRSVRSV infection (03)(MedImmune) MylotargCD33Relapsed CD33-positive AML (calicheamin) (Celltech/Wyeth-Ayerst) CampathCD52B cell CLL (Millenium Ph/Schering AG) Zevalin CD20Non-Hodgkin’s lymphoma (I111 & Y90) (IDEC) HumiraTNFRhematoid arthritis 149.0(1Q/04)(Abbot) Xolair IgEAsthma 30.0(1Q/04)(Genentech/Novartis) BexxarCD20Non-Hodgkin’s lymphoma (I131) (03)(Corixa/Glaxo-SmithKline) RaptivaCD11aMod.. severe plaque psoriasis, psoriatic arthritis 6.3(1Q/04)(Xoma/Genentech) AvastinVEGFMetastatic carcinoma of the colon or rectum 133.0(2Q/04)(Genetech) ErbituxEGFREGFR-expressing, metastatic colorectal cancer 17.5(1Q/04)(Brystol-Myer-Squibb, Imclone) EmbrelTNFRA, Polyarticular juvenile RA, psoriatic arthritis, 397,0(1Q/04)(Amgen) ankylosing spondylitis, psoriasis Murine Antibody Chimeric Antibody Humanized Antibody

The market for therapeutic antibodies is exponentially growing !!

Chronicle of Therapeutic Abs Source: Duckworth J, Fisken J, “Investing in new therapeutic technologies.” Current Drug Discovery. 2002;2:29–32. Reprinted with permission.

Sources of Therapeutic Abs 1.Human B cell (Recombinant DNA technology) Source of B cell (amount, validation) Ethical Issues on Immunization 2. Hybridoma technology Mouse immunization Limited Screening HAMA (human anti-mouse antibody response) effect  Ab engineering required 3. Phage display Naive, immunized and synthetic libraries 4. Immunized animal Immunogenecity problem

Higher chance of good clone selection

Process for Ther. Ab develop. Target Discovery - Genomics - Proteomics Antibody Generation - Naïve - Immunized - Fab - scFv - Domain New format - Andrea’s group - Plastibody Conformation of antigen Polishing - Phage - Phagemid - Non-biological Affinity maturation Localization Half life extension - Drug conjugate - Isotope labeling - Enzyme labeling (ADEPT) - Bispecific Production Mammalian - Prokaryotic - Plant - Transgenic chicken - Cell panning (Raven, Affitech’s CBAS, Health Canada) - Antibody repertoire directed - Animal model based (Lexicon) Pre- & clinical Trial Every good antibody can be a drug! Humanization